There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > BAFFR


Brief Information

Name:B-cell activating factor receptor
Target Synonym:B-Cell Activation Factor Receptor,BAFF-R,TNF Receptor Superfamily Member 13C,BLyS Receptor 3,B-Cell-Activating Factor Receptor,TNFRSF13C,B Cell-Activating Factor Receptor,Prolixin,BAFFR,BR3,Tumor Necrosis Factor Receptor Superfamily Member 13C,CVID4,Tumor
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:1
Lastest Research Phase:Phase 3 Clinical

Product ListCompare or Buy

Part of Bioactivity data


Immobilized Human BAFF, Fc Tag, active trimer (Cat. No. BAF-H5261) captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Human BAFFR, Llama IgG2b Fc Tag, low endotoxin (Cat. No. BAR-H5258) with an affinity constant of 44.5 nM as determined in a SPR assay (Biacore T200) (Routinely tested).


Immobilized Biotinylated Human BAFF, Avitag,Fc Tag (active trimer) (MALS verified) (Cat. No. BAF-H82F3) on SA Chip can bind Human BAFFR, Fc Tag (Cat. No. BAR-H5257) with an affinity constant of 26.7 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

Synonym Name



BAFF receptor (B-cell activating factor receptor, BAFF-R), also known as tumor necrosis factor receptor superfamily member 13C (TNFRSF13C), is a membrane protein of the TNF receptor superfamily which recognizes BAFF. B-cell activating factor (BAFF) enhances B-cell survival in vitro and is a regulator of the peripheral B-cell population. Overexpression of BAFF in mice results in mature B-cell hyperplasia and symptoms of systemic lupus erythematosus (SLE). Also, some SLE patients have increased levels of BAFF in serum. Therefore, it has been proposed that abnormally high levels of BAFF may contribute to the pathogenesis of autoimmune diseases by enhancing the survival of autoreactive B cells.

Clinical and Translational Updates

Related Molecule

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Ianalumab NOV-5; VAY-736 Phase 3 Clinical Morphosys Ag, Novartis Pharma Ag Arthritis, Rheumatoid; Idiopathic Pulmonary Fibrosis; Sjogren's Syndrome; Lymphoma, Large B-Cell, Diffuse; Multiple Sclerosis; Lupus Erythematosus, Systemic; Hepatitis, Autoimmune; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell; Pemphigus Details

This web search service is supported by Google Inc.